What Are the Fundamentals Of EXEL?

Mid-cap Health Care company Exelixis has moved -0.6% so far today on a volume of 545,477, compared to its average of 2,298,606. In contrast, the S&P 500 index moved 0.0%.

Exelixis trades -15.84% away from its average analyst target price of $25.82 per share. The 17 analysts following the stock have set target prices ranging from $18.0 to $32.0, and on average have given Exelixis a rating of buy.

If you are considering an investment in EXEL, you'll want to know the following:

  • Exelixis has moved 33.0% over the last year, and the S&P 500 logged a change of 17.0%

  • Based on its trailing earnings per share of 0.29, Exelixis has a trailing 12 month Price to Earnings (P/E) ratio of 74.9 while the S&P 500 average is None

  • EXEL has a forward P/E ratio of 24.1 based on its forward 12 month price to earnings (EPS) of $0.9 per share

  • The company has a price to earnings growth (PEG) ratio of 1.89 — a number near or below 1 signifying that Exelixis is fairly valued compared to its estimated growth potential

  • Its Price to Book (P/B) ratio is 2.88 compared to its sector average of None

  • Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States.

  • Based in Alameda, the company has 1,223 full time employees and a market cap of $6.76 Billion.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.

IN FOCUS